Champions Oncology, Inc. CSBR
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.65% | 4.36% | -1.10% | 9.06% | 10.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.65% | 4.36% | -1.10% | 9.06% | 10.11% |
| Cost of Revenue | 3.85% | 8.85% | 10.56% | -1.53% | 1.81% |
| Gross Profit | 9.63% | -0.12% | -12.05% | 22.14% | 20.56% |
| SG&A Expenses | 27.50% | 21.23% | 19.80% | 8.80% | -3.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.34% | 16.04% | 16.00% | 3.78% | -1.51% |
| Operating Income | -130.96% | -121.25% | -133.06% | 799.72% | 199.05% |
| Income Before Tax | -131.40% | -120.08% | -137.46% | 470.60% | 182.71% |
| Income Tax Expenses | 400.00% | 432.43% | -111.54% | -94.74% | -113.16% |
| Earnings from Continuing Operations | -138.84% | -124.99% | -136.46% | 506.52% | 186.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.78% | -124.34% | -135.97% | 511.71% | 186.02% |
| EBIT | -130.96% | -121.25% | -133.06% | 799.72% | 199.05% |
| EBITDA | -91.20% | -94.65% | -109.17% | 176.85% | 490.33% |
| EPS Basic | -136.97% | -123.89% | -135.70% | 510.71% | 185.49% |
| Normalized Basic EPS | -123.37% | -115.39% | -128.27% | 1,452.17% | 204.33% |
| EPS Diluted | -141.13% | -126.03% | -138.19% | 368.99% | 173.11% |
| Normalized Diluted EPS | -125.65% | -116.56% | -129.64% | 1,044.63% | 195.44% |
| Average Basic Shares Outstanding | 1.19% | 1.35% | 1.36% | 1.21% | 1.03% |
| Average Diluted Shares Outstanding | 0.41% | -0.24% | -0.23% | 2.02% | 2.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |